Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Accounts Payables (2016 - 2025)

International Stem Cell (ISCO) has disclosed Accounts Payables for 16 consecutive years, with $265000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 17.45% to $265000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $265000.0, a 17.45% decrease, with the full-year FY2024 number at $186000.0, down 48.9% from a year prior.
  • Accounts Payables was $265000.0 for Q3 2025 at International Stem Cell, down from $397000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $635000.0 in Q1 2022 to a low of $186000.0 in Q4 2024.
  • A 5-year average of $401263.2 and a median of $377000.0 in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: skyrocketed 56.27% in 2021, then crashed 48.9% in 2024.
  • International Stem Cell's Accounts Payables stood at $508000.0 in 2021, then plummeted by 36.61% to $322000.0 in 2022, then grew by 13.04% to $364000.0 in 2023, then crashed by 48.9% to $186000.0 in 2024, then soared by 42.47% to $265000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Accounts Payables are $265000.0 (Q3 2025), $397000.0 (Q2 2025), and $457000.0 (Q1 2025).